Key result
Aliskiren is linked to sustained ~87% lower plasma renin activity in hypertensive hemodialysis patients.
Why the study?
The long-term effects of aliskiren on blood pressure and renin-angiotensin-aldosterone system inhibition in hypertensive hemodialysis patients remain to be elucidated.
Observational (n=25)
Open-label
Yes
Absolute Event Rate: 0.3% vs 4.1%
p-value: p=<0.05
Sustained renin inhibition with aliskiren appears feasible in hypertensive hemodialysis patients; leaves open effects on clinical outcomes.
OBJECTIVE: The long-term effects of aliskiren in hypertensive hemodialysis patients remain to be elucidated. DESIGN: In this post hoc analysis, we followed up 25 hypertensive hemodialysis patients who completed 8-week aliskiren treatment in a previous study for 20 months to investigate the blood pressure-lowering effect and inhibitory effect on the renin-angiotensin-aldosterone system. RESULTS: Among the 25 patients, eleven patients continued with aliskiren treatment. Blood pressure (± standard deviation) decreased from 175 ± 18/80 ± 11 mmHg at baseline to 156 ± 20/76 ± 9 mmHg at month 20. Plasma renin activity, angiotensin I, and angiotensin II decreased from baseline to month 20 (plasma renin activity (ng/mL/h): 2.3 ± 2.6 to 0.3 ± 0.4 (P < 0.05), angiotensin I (pg/mL): 909.1 ± 902.5 to 41.5 ± 14.8 (P < 0.05), angiotensin II (pg/mL): 41.5 ± 45.8 to 11.0 ± 4.9 (P < 0.05)). CONCLUSION: Long-term treatment with aliskiren provides effective blood pressure lowering and inhibition of the renin-angiotensin-aldosterone system, which are sustained over 20 months in hypertensive hemodialysis patients.
No takes yet. Share an insight, caveat, or question.
Morishita et al. (2012) conducted an observational in Hypertension in hemodialysis patients (n=25). Aliskiren vs. Aliskiren withdrawal (standard antihypertensives) was evaluated on Plasma renin activity (ng/mL/h) at 20 months (p=<0.05). Long-term treatment with aliskiren sustained significant inhibition of plasma renin activity (decreasing from 2.3 to 0.3 ng/mL/h, P<0.05) over 20 months in hypertensive hemodialysis patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: